Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Proton-pump inhibitors as a protective treatment for high-risk patients receiving treatment with NSAIDs

Nature Clinical Practice Rheumatology volume 3, pages 694–695 (2007)Cite this article

boxed-textVonkeman HE et al. (2007) Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case–control study. Arthritis Res Ther 9: R52

NSAID users who are over 70 years old, have concurrent cardiovascular disease, or who have had ulcers previously and are thus at high risk of gastrointestinal adverse events, should receive concomitant treatment with proton-pump inhibitors

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lanas A et al. (2007) Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102: 507–515

    Article  CAS  Google Scholar 

  2. Chan FK et al. (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344: 967–973

    Article  CAS  Google Scholar 

  3. Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  CAS  Google Scholar 

  4. Rostom A et al. (2007) Gastrointestinal safety of cyclooxygenase-2 inhibitors: a cochrane collaboration systematic review. Clin Gastroenterol Hepatol 5: 818–828

    Article  Google Scholar 

  5. Chan FK et al. (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369: 1621–1626

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, Hong Kong fklchan@cuhk.edu.hk

Authors and Affiliations

  1. FKL Chan is a Professor of Medicine and Chief of Gastroenterology & Hepatology in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong, and an honorary consultant physician at the Prince of Wales Hospital in Hong Kong.,

    Francis KL Chan

Authors
  1. Francis KL Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

FKL Chan has received consultant fees from AstraZeneca, Pfizer and TAP Pharmaceuticals. Dr Chan has also received lecture fees from AstraZeneca and TAP Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, F. Proton-pump inhibitors as a protective treatment for high-risk patients receiving treatment with NSAIDs. Nat Rev Rheumatol 3, 694–695 (2007). https://doi.org/10.1038/ncprheum0650

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0650

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing